Mumma JM, Weaver BW, Morgan JS, Ghassemian G, Gannon PR, Burke KB, Berryhill BA, MacKay RE, Lee L, Kraft CS. Connecting pathogen transmission and healthcare worker cognition: a cognitive task analysis of infection prevention and control practices during simulated patient care. BMJ Qual Saf. 2023 Nov 28. doi: 10.1136/bmjqs-2023-016230
Wood D, Kosa K, Brown D, Ehrlich OG, Higgins PDR, Heller C. Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: evidence from a choice-based conjoint analysis. Crohns Colitis 360. 2020 Jan;2(1). doi: 10.1093/crocol/otz048
Christensen T, Riis AH, Hatch EE, Wise LA, Nielsen MG, Rothman KJ, Toft Sorensen H, Mikkelsen EM. Costs and efficiency of online and offline recruitment methods: a web-based cohort study. J Med Internet Res. 2017 Mar 1;19(3):e58. doi: 10.2196/jmir.6716
Murphy DR, Laxmisan A, Reis BA, Thomas EJ, Esquivel A, Forjuoh SN, Parikh RC, Khan MM, Singh H. Electronic health record-based triggers to detect potential delays in cancer diagnosis. BMJ Qual Saf. 2014 Jan;23(1):8-16. doi: 10.1136/bmjqs-2013-001874
Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolanos-Meade J, Brown JMY, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep;70(17):1518-27.
Warttig S, Elliott N. Partially updating a guideline to improve its implementation. Presented at the G-I-N Conference; August 2013. San Francisco, CA. [abstract] BMJ Qual Saf. 2013; 22(Suppl 1):A32. doi: 10.1136/bmjqs-2013-002293.93
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009 Mar 1;66(5):469-80.